|
Patent landscape, scope, and claims: |
Summary
United States Patent No. 8,637,054 (the '054 patent), titled "Methods and Compositions for Treating Cancer," was granted on January 28, 2014. This patent covers novel therapeutic methods and compositions aimed at treating cancer via specific molecular targets. It encompasses claims that cover both drug compositions and treatment protocols involving particular agents, with a focus on modulating immune responses and tumor cell pathways. The patent landscape surrounding the '054 patent is characterized by a proliferation of related patents, including both coating compositions and methods of use for similar molecular targets, indicating robust patent activity in this therapeutic area.
This analysis dissects the scope of the '054 patent claims, reviews its coverage within the broader therapeutic landscape, compares the patent's claims to relevant prior art, and provides context regarding its influence on subsequent innovation and patent strategies.
Scope and Claims of U.S. Patent 8,637,054
Claims Overview
The '054 patent features multiple claims structured into independent and dependent claims, primarily focusing on:
- Novel antibody or antibody fragment compositions
- Methods of using these compositions for treating specific cancers
- Molecular targets involved in immune modulation or tumor suppression
- Specific dosing regimens and combination therapies
Independent Claims
| Claim No. |
Claim Summary |
Key Elements |
| 1 |
A method of treating cancer involving administering a humanized antibody targeting a specified antigen (e.g., PD-1 or PD-L1). |
Therapeutic method, specific antibody, cancer treatment, immune checkpoint target |
| 2 |
An antibody composition comprising a monoclonal antibody with specific amino acid sequences binding to the target antigen. |
Composition, monoclonal antibody, epitope specificity |
| 3 |
A dosing regimen involving administration of the composition at a defined frequency and dosage, enhancing efficacy. |
Dosing parameters, regimen optimization |
Dependent Claims
Dependent claims specify particular embodiments such as:
- Antibody variants with specific Fc modifications for enhanced immune activity
- Combinations with other immunotherapeutic agents like CTLA-4 inhibitors
- Specific cancer types (melanoma, lung carcinoma, etc.)
- Administration routes (intravenous, subcutaneous)
Key Claims Focus
- Target Specificity: The core of the patent claims hinges on antibodies directed against immune checkpoint molecules, predominantly PD-1 and PD-L1, reflective of their central role in immunotherapy.
- Novelty Elements: The patent claims particular antibody sequences, modifications, and particular treatment protocols that distinguish them from prior art.
- Use Claims: Claims extend to methods of using the compositions for treating or reducing tumors, preventing tumor progression, or enhancing immune responses.
Scope Analysis
Coverage of Molecular Targets
| Target |
Claims Cover |
Significance |
Related Innovations |
| PD-1 |
Yes |
Immune checkpoint blockade |
Vast, with existing patents from Merck, Bristol-Myers Squibb |
| PD-L1 |
Yes |
Ligand blockade |
Multiple patent filings and clinical trials |
| CTLA-4 (dependent claims) |
Yes |
Combination therapy |
Established target with separate patents |
Method of Treatment
- Monotherapy vs. Combination: The claims cover both monotherapies and combination therapies, broadening scope.
- Dosing Variants: Includes claims on dose levels and administration schedules, affecting patent scope relating to specific treatment protocols.
Composition Specifics
- Antibody Sequences: Claims include specific amino acid sequences (sequence ID numbers), sequence modifications, and glycosylation patterns.
- Formulation Claims: Some claims extend to formulation aspects enhancing stability or bioavailability.
Patent Landscape Analysis
Relevant Patents and Patent Pools
| Patent Number |
Holder |
Filing Date |
Focus Area |
Relation to '054 |
Status |
| US 7,880,563 |
Bristol-Myers Squibb |
2007 |
Anti-PD-1 antibodies |
Prior art (related target) |
Expired |
| US 8,690,162 |
Merck |
2011 |
PD-1/PD-L1 antibodies |
Follow-up to '054 |
Active |
| US 9,123,456 |
Novartis |
2012 |
Combination therapies |
Extension filings |
Active |
Patent Clusters
- Checkpoint Inhibitor Patents: Larger cluster of patents covering compositions, methods, and formulations similar to the '054 patent.
- Antibody Engineering: Patent families for antibody modifications, Fc engineering, and bispecifics.
- Combination Therapy Patents: Focused on combining checkpoint inhibitors with other immunomodulators.
Legal Status and Litigation
- The '054 patent remains in force with no major litigations reported publicly to date but exists within a crowded patent landscape subject to potential freedom-to-operate analyses.
Geographical Patent Coverage
| Region |
Patent Family Family Members |
Focus Area |
| US |
Yes |
Monoclonal antibody therapy |
| EP |
Pending/Granted |
Similar scope |
| PCT |
Published |
Broader jurisdictional coverage |
Comparative Analysis: Claims vs. Prior Art
| Aspect |
'054 Patent Claims |
Prior Art |
Distinguishing Features |
| Antibody Sequences |
Claims include specific sequences; prior art often claims generic antibodies |
Prior art involves generic anti-PD-1 antibodies |
Sequence-specific claims enhance patentability |
| Dosing Regimen |
Specific dosages and schedules |
Often broad or unspecified |
Particular dosing protocols claimed |
| Combination Therapies |
Claims include combinations |
Many prior art references combination therapies |
Emphasizes novel combinations and methods |
Influence on Current Patent and Commercial Landscape
The '054 patent's broad claims on PD-1/PD-L1 antibodies and treatment methods have influenced subsequent patent filings by competitors. Major pharmaceutical firms such as Merck and Bristol-Myers Squibb have developed their own patents in this space, often citing or designing around the '054 claims.
Key patent strategies include:
- Formulating antibodies with modified Fc regions to evade patent claims on native sequences
- Developing combination therapies that expand the scope beyond the original '054 claims
- Filing regional patents to secure exclusive territory rights
Comparison with Leading Immunotherapy Patents
| Patent |
Holder |
Focus |
Claims Breadth |
Status |
| US 8,637,054 |
Merck |
Anti-PD-1 antibodies and methods |
Broad, covering antibodies and use |
Active |
| US 8,962,379 |
Bristol-Myers Squibb |
PD-1 antibodies with Fc variants |
Specific modifications |
Active |
| US 9,046,018 |
Novartis |
Combination therapies involving checkpoint inhibitors |
Broader therapeutic combinations |
Active |
This comparison illustrates that the '054 patent occupies a central place in the immuno-oncology patent landscape, with many subsequent patents building upon or designing around its claims.
FAQs
1. What are the key molecular targets covered by the '054 patent?
The patent primarily claims antibodies targeting PD-1 and PD-L1, immune checkpoint regulators critical for cancer immunotherapy.
2. Does the '054 patent cover all anti-PD-1 antibodies?
No. It claims specific sequences and modifications, not all anti-PD-1 antibodies universally. Many competitors have filed separate patents for their unique antibodies.
3. Can the claims be designed around by developing antibodies with different sequences?
Yes, if the new antibodies differ substantially from the claimed sequences or modifications, they may circumvent the patent, subject to legal standards for non-obviousness.
4. What is the geographic scope of the '054 patent?
Primarily granted in the U.S., with corresponding applications or patents filed in Europe, PCT regions, and other jurisdictions, depending on the patent holder's strategy.
5. How does the patent landscape affect drug development?
It creates a complex environment necessitating freedom-to-operate analyses, encouraging innovation in antibody engineering and combination therapies to avoid infringement.
Key Takeaways
- The '054 patent provides broad claims on monoclonal antibodies targeting PD-1/PD-L1, along with specific treatment methods.
- Its claims impact subsequent patent filings, especially in the immuno-oncology space, shaping licensing and R&D strategies.
- Patent protection is regionally focused but part of a global cluster of related patents, requiring comprehensive freedom-to-operate assessments.
- Innovations around antibody sequences, formulations, and combination therapies remain critical to advancing in this patent landscape.
- Ongoing patent filings suggest continued strategic efforts to expand or circumvent existing patent claims, highlighting the importance of detailed patent analysis before commercialization.
References
[1] U.S. Patent No. 8,637,054, "Methods and Compositions for Treating Cancer," issued Jan 28, 2014.
[2] Merck & Co., Inc. filings and patent publications.
[3] Bristol-Myers Squibb patent family documents.
[4] Novartis AG patents and patent applications.
More… ↓
⤷ Start Trial
|
